Six patients with cyclic neutropenia were treated with recombinant human granulocyte colony-stimulating factor (G-CSF) for 3 to 15 months. All had a history of recurrent aphthous stomatitis, pharyngitis, lymphadenopathy, fever, and numerous infections during periods of neutropenia. Serial blood-cell counts, findings on bone marrow examination, and signs and symptoms were evaluated before and during the daily administration of G-CSF (3 to 10 micrograms per kilogram of body weight per day), either intravenously or subcutaneously. The kinetics of labeled autologous blood neutrophils and the migration of neutrophils to skin chambers were also measured. Recombinant human G-CSF increased the mean (+/- SEM) neutrophil counts from 717 +/- 171 per microliter to 9814 +/- 2198 per microliter (P = 0.009). In five of the six patients, the cycling of blood-cell counts continued, but the length of the period decreased from 21 to 14 days. The number of days of severe neutropenia was reduced (P = 0.002). Neutrophil turnover increased almost four-fold (P = 0.005), whereas neutrophil migration to a skin chamber was normal. G-CSF therapy reduced the frequency of oropharyngeal inflammation, fever, and infections in these patients. During the first 40 months of treatment, no typical mouth ulcers or bacterial infections occurred; recurrent gingivitis improved. We conclude that G-CSF is effective for the treatment of cyclic neutropenia in humans.
Source Information
Department of Medicine, University of Washington School of Medicine, Seattle.
This article has been cited by other articles:
Berliner, N.
(2008). Lessons from congenital neutropenia: 50 years of progress in understanding myelopoiesis. Blood
111: 5427-5432
[Abstract][Full Text]
James, R M, Kinsey, S E
(2006). The investigation and management of chronic neutropenia in children. Arch. Dis. Child.
91: 852-858
[Abstract][Full Text]
Kurzrock, R.
(2005). Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited. Clin. Cancer Res.
11: 1361-1367
[Abstract][Full Text]
Yanay, O., Barry, S. C., Katen, L. J., Brzezinski, M., Flint, L. Y., Christensen, J., Liggitt, D., Dale, D. C., Osborne, W. R. A.
(2003). Treatment of canine cyclic neutropenia by lentivirus-mediated G-CSF delivery. Blood
102: 2046-2052
[Abstract][Full Text]
Lakshman, R, Finn, A
(2001). Neutrophil disorders and their management. J. Clin. Pathol.
54: 7-19
[Abstract][Full Text]
Dale, D. C., Person, R. E., Bolyard, A. A., Aprikyan, A. G., Bos, C., Bonilla, M. A., Boxer, L. A., Kannourakis, G., Zeidler, C., Welte, K., Benson, K. F., Horwitz, M.
(2000). Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood
96: 2317-2322
[Abstract][Full Text]
Dinauer, M. C., Lekstrom-Himes, J. A., Dale, D. C.
(2000). Inherited Neutrophil Disorders: Molecular Basis and New Therapies. ASH Education Book
2000: 303-318
[Abstract][Full Text]
Haurie, C., Dale, D. C., Mackey, M. C.
(1998). Cyclical Neutropenia and Other Periodic Hematological Disorders: A Review of Mechanisms and Mathematical Models. Blood
92: 2629-2640
[Abstract][Full Text]
Souid, A. K.
(1995). Congenital Cyclic Neutropenia. CLIN PEDIATR
34: 151-155
Metcalf, D
(1991). Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Science
254: 529-533
[Abstract]
Gorman, S. E., Plaisance, K.
(1991). Application of Products Produced Through Biotechnology in Infectious Diseases. Journal of Pharmacy Practice
4: 103-116
Lindley, C. M., Gordon, T. R.
(1991). Application of Biotechnology Products in Oncology. Journal of Pharmacy Practice
4: 117-130
Previous
